Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance with Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisements confirming completion of dispatch of notices to the eligible members of the Company as published in Business Standard (English - All Edition) and in Navashakthi (Marathi Edition). Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 13, 2021 for Pronomz Ventures LLP Strides Pharma Science Ltd - 532531 - Reg. 34 (1) Annual Report
This is to inform you that the 30th Annual General Meeting ('AGM') of the Company is scheduled to be held on Friday, September 3, 2021 at 12:30 hrs IST through Video Conference/ Other Audio-Visual Means. As required under SEBI Listing Regulations, we are enclosing herewith Notice of the AGM and Annual Report for FY 2020-21 which is being sent through electronic mode to the Members of the Company. A copy of the same is also available on the Company's website www.strides.com This is for your information and records.
Drug companies see US sales plunging in Q1FY22 amidst pricing pressure, lack of new approvals
Strides Pharma, Cipla among the companies. Strides Pharma reports net loss of Rs 21.23 crore in the first quarter of FY22. MD CEO says firm has not seen the kind of price erosion it has seen in Q1FY22.
Q1FY22 Result Announced for Strides Pharma Science Ltd.
Strides Pharma Science Limited (“Strides”) today announced that its wholly owned subsidiaries have entered into definitive agreements with subsidiaries of Endo International plc (“Endo”) to acquire its manufacturing facility at Chestnut Ridge, New York and a basket of ANDAs. Strategic Rationale Over the last few years, Strides US business has seen a significant ramp up driven by portfolio expansion and strengthening of frontend presence. US is now the largest market for Strides contributing 48% of FY21 consolidated revenue The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US and a basket of ANDAs cutting across multiple therapeutic segments. The cumulative addressable market for the acquired portfolio is US$4.7bn (IQVIA MAT May 2021). The facility at Chestnut Ridge, New York has an annual capacity of 2 billion units across semisolids, liquids, nasal sprays along with oral solids. The facility is also registered with the Drug Enforcement Administration (DEA) enabling manufacturing of controlled substances Considering the COVID-19 disruptions, this facility being in the US will enable us to mitigate supply chain related bottleneck and will drive logistics related synergies for the US business The facility has undergone several successful USFDA inspections in the past and has received the Establishment Inspection Report (EIR). This site mirrors the capabilities of our flagship facility at Bengaluru, India, and will help further de-risk our manufacturing footprint Being in the US, the facility will be able to participate in various federal government procurement programs including the Department of Veterans Affairs. The acquisition further strengthens our ability to cater to federal contracts The acquired portfolio has 20 commercial products and a basket of dormant ANDA’s which will help fast track our new launch strategy for US markets with 5-6 new product introductions every quarter Strides is pleased to welcome a strong talent pool having several years of global experience as part of acquisition Transaction details Under the terms of the agreement, Strides will pay ~US$24m for the acquisition The transaction will be financed by a combination of internal accruals and debt financing The transaction is expected to close in CY2021 subject to customary closing conditions Commenting on the development, Dr. R.Ananthanarayanan, Managing Director & CEO, remarked “Over the last few years our US business has witnessed a healthy growth momentum and has now attained a critical scale. The acquisition we have announced today is a very good strategic fit for the business and will help further accelerate our growth momentum for the US market. With this acquisition we have doubled our US portfolio with a potential to launch 5-6 new products each quarter going forward. We believe with the combined product portfolio, experienced management team, established frontend and a diversified manufacturing footprint we have created a strong foundation to achieve our previously stated growth ambition for the market. On completion of the transaction, our immediate focus will be on seamless integration of people and the acquired assets onto Strides platform” Result PDF
Strides Pharma Science posts Q1 net loss of Rs 208.56 crore
The company had posted a net profit of Rs 101.84 crore for the corresponding period of the previous financial year, Strides Pharma Science said in a regulatory filing. Strides Pharma Science Ltd - 532531 - Stelis Biopharma Appoints Mark W. Womack As The New CEO
Please find attached Press Release issued by Stelis Biopharma Ltd, the biopharmaceutical division of Strides titled: 'Stelis Biopharma appoints Mark W. Womack as the new CEO' Strides Pharma Science Ltd - 532531 - Stelis Biopharma Appoints Mark W. Womack As The New CEO
Please find attached Press Release issued by Stelis Biopharma Ltd, the biopharmaceutical division of Strides titled: 'Stelis Biopharma appoints Mark W. Womack as the new CEO' Strides Pharma Science Ltd - 532531 - Stelis Biopharma Strengthens Its Board With Experienced Industry Leadership And Diversity
Please find attached Press Release issued by Stelis Biopharma Ltd, the biopharmaceutical division of Strides titled: 'Stelis Biopharma strengthens its Board with experienced industry leadership and diversity'